Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Abstract: This invention relates to methods for identifying compound capable of activating p53-responsive transcriptional activity in a p53-deficient tumor cell and the use of these compounds.

Abstract: Compositions and methods for treating cancer in a subject in need thereof are provided according to aspects of the present disclosure which include both cetuximab and ISC-4, as a combination formulation or as separate formulations. Methods of treating cancer in a subject in need thereof are provided according to aspects of the present disclosure wherein the subject has cancer characterized by wild-type KRAS wherein the methods include administering a combination of cetuximab and ISC-4 as a combination formulation or separately, and wherein administration of the combination of cetuximab and ISC-4 provides a synergistic anti-cancer effect, treating the cancer.

Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.

Abstract: This invention relates to the use of in-vivo hyperspectral imaging to monitor angiogenesis. Specifically, the invention provides systems and methods of obtaining hyperspectral images of a field of view comprising an area sought to be monitored.

Abstract: This invention relates to embodiment to a molecular beacon, methods and kits for the detection of expression of p21(Waf1/Cip1), in response to chemotherapy. Specifically, the introduction of a phosphorothioate-modified p21-beacon by transfection in human tumor cells yields increased signal in a dose dependent manner.

Abstract: Provided are compositions and methods for controlling, modulating or regulating extrinsically-induced apoptosis in a population of cells, comprising treating the cell population with a synergistically combined composition comprising an amount of TRAIL in conjunction with an amount of at least one reagent acting on mitochondrial pathways of the cells, which in combination is sufficient to induce cellular apoptosis, such that the apoptosis-inducing effect of the combination is greater than that of TRAIL alone, or the at least one reagent alone, or the additive individual apoptotic effects of TRAIL and the at least one reagent. However, TRAIL-sensitive normal cells are protected from the extrinsically induced apoptosis by treatment with a specific caspase inhibitor, such as a caspase 9 inhibitor.

Abstract: This invention relates to modulating cellular apoptosis in an animal by regulating the quantity of functional KILLER/DR5 receptor protein molecules in the target cell(s) of said animal, increasing the effectiveness of certain therapies such as chemotherapy and radiotherapy. Such modulation increases the difference in toxicity response between target cell(s) and non-target cell(s) in response to a therapy or treatment and comprises upregulation of wild-type proteins in cells targeted for increased apoptosis or upregulation of loss-of-function proteins in cells targeted for decreased apoptosis. The methods of this invention comprise administering a nucleic acid sequence encoding a wild-type KILLER/DR5 receptor protein or a nucleic acid sequence encoding a loss-of-function mutant KILLER/DR5 receptor protein to said animal. The pharmaceutical compositions of this invention comprise a loss-of-function KILLER/DR5 receptor protein.

Abstract: Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain cancer in a subject in need thereof.